|
Dr. Dow joined Cell Genesys in March 2005 and serves as senior vice president of medical affairs. He currently oversees market, label expansion and post-marketing development activities associated with Cell Genesys' product portfolio. Prior to Cell Genesys, he was chief executive officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also previously held senior executive positions with Quantanova and Scotia Holdings, plc. Prior to that, Dr. Dow was head of Global Drug Development with Hoffman-La Roche in Basel, Switzerland and previously was with Syntex Corporation for over 10 years in various senior positions in drug development. Dr. Dow holds a B.Sc. in Medical Science from the University of St. Andrews and his medical qualification, an MBChB degree, from the University of Dundee in Scotland. He also is a Fellow of the Royal College of Physicians of Edinburgh. | 